ISOVUE 128 INJ 26% 26 % — DIN 01958011
IOPAMIDOL : 26 % · SQUIBB DIAGNOSTICS, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC. · LIQUID · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is ISOVUE 128 INJ 26%?
ISOVUE 128 INJ 26% 26 % contains IOPAMIDOL : 26 %. It is listed in the Health Canada Drug Product Database under DIN 01958011, held by SQUIBB DIAGNOSTICS, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC., supplied as LIQUID for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 30-Jul-1998. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
How much does Iopamidol cost around the world?
Iopamidol is listed on 6 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Brazil publishes a preco fabrica (ex-factory ceiling); Greece publishes a producer price (ex-factory); Hungary publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Hungary | producer price (ex-factory) | 4 | 14 | HUF███.██ |
| Saudi Arabia | public | 4 | 11 | SAR███.██ |
| South Africa | single exit price | 7 | 7 | ZAR███.██ |
| Brazil | preco fabrica (ex-factory ceiling) | 1 | 6 | BRL███.██ |
| Greece | producer price (ex-factory) | 6 | 6 | EUR███.██ |
| Romania | max producer price | 2 | 5 | RON███.██ |
49 pack listings across 24 brand entries and 5 price bases, refreshed 03 Sep 2026. Ranges span every Iopamidol pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Iopamidol in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
4 holders have a Canadian DIN containing Iopamidol, across 15 DINs, of which 5 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| BRACCO IMAGING CANADA | 6 | 5 | ISOVUE 128 INJECTION, ISOVUE 200 INJECTION, ISOVUE 300 INJECTION, ISOVUE 370 INJECTION, ISOVUE MULTIPACK-300, +1 more | Sourceable in Canada |
| SQUIBB DIAGNOSTICS, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC. | 4 | 0 | ISOVUE 128 INJ 26%, ISOVUE 200 INJ 41%, ISOVUE 300 INJ 61%, ISOVUE 370 INJ 76% | No marketed DIN |
| PHARMASCIENCE INC | 3 | 0 | PMS-IOPAMIDOL | No marketed DIN |
| HOSPIRA HEALTHCARE ULC | 2 | 0 | IOPAMIDOL INJECTION USP | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 26 % |
|---|---|
| Dosage form | LIQUID |
| Route | INTRAVENOUS |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Iopamidol |
|---|---|
| ATC code | V08AB04 |
| AHFS class | 36:68.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 01958011 |
|---|---|
| DIN (unpadded, as printed on some documents) | 1958011 |
| Brand name | ISOVUE 128 INJ 26% |
| Generic / active ingredient | IOPAMIDOL : 26 % |
| Market authorization holder | SQUIBB DIAGNOSTICS, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC. |
| Health Canada schedule | Ethical |
| ATC code | V08AB04 |
| ATC anatomical main group | V — Various |
| ATC therapeutic subgroup | V08AB |
| Current status | CANCELLED POST MARKET |
| Status date | 30-Jul-1998 |
| Original market date | 1988-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
5 of 15 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ISOVUE 200 INJECTION | 41 % | SOLUTION | BRACCO IMAGING CANADA | MARKETED | 02229013 |
| ISOVUE 300 INJECTION | 61 % | LIQUID | BRACCO IMAGING CANADA | MARKETED | 02229021 |
| ISOVUE 370 INJECTION | 76 % | LIQUID | BRACCO IMAGING CANADA | MARKETED | 02229048 |
| ISOVUE MULTIPACK-300 | 61 % | LIQUID | BRACCO IMAGING CANADA | MARKETED | 02242122 |
| ISOVUE MULTIPACK-370 | 76 % | LIQUID | BRACCO IMAGING CANADA | MARKETED | 02242121 |
| IOPAMIDOL INJECTION USP | 61 % | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED PRE MARKET | 02231260 |
| IOPAMIDOL INJECTION USP | 76 % | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED PRE MARKET | 02231261 |
| ISOVUE 128 INJECTION | 26 % | LIQUID | BRACCO IMAGING CANADA | CANCELLED POST MARKET | 02229005 |
| ISOVUE 200 INJ 41% | 41 % | LIQUID | SQUIBB DIAGNOSTICS, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC. | CANCELLED POST MARKET | 01958003 |
| ISOVUE 300 INJ 61% | 61 % | LIQUID | SQUIBB DIAGNOSTICS, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC. | CANCELLED POST MARKET | 01958976 |
2 · Same class — other molecules in ATC V08AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Iopamidol | IOPAMIDOL INJECTION USP · ISOVUE 128 INJ 26% · ISOVUE 128 INJECTION · ISOVUE 200 INJ 41% · +8 more | 15 | 5 | Yes |
| Iodixanol | IODIXANOL INJECTION 270 · IODIXANOL INJECTION 320 · VISIPAQUE 270 · VISIPAQUE 320 | 4 | 4 | Yes |
| Iohexol | OMNIPAQUE 180 · OMNIPAQUE 180 LIQ SAR 388MG/ML · OMNIPAQUE 240 · OMNIPAQUE 240 LIQ IV SAR 518MG/ML · +4 more | 8 | 3 | Yes |
| Iopromide | ULTRAVIST 240 · ULTRAVIST 300 · ULTRAVIST 370 | 3 | 2 | Yes |
| Ioversol | OPTIRAY 160 · OPTIRAY 160 (ULTRAJECT) · OPTIRAY 240 · OPTIRAY 240 (ULTRAJECT) · +7 more | 11 | 0 | Not in Canada |
| Iotrolan | OSMOVIST 240 - LIQ INT 513MG/ML · OSMOVIST 300 - LIQ INT 641MG/ML | 2 | 0 | Not in Canada |
| Ioxaglic Acid | HEXABRIX 200 · HEXABRIX 320 | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC V08A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| V08AA | Diatrizoic Acid · Iotalamic Acid · Ioxitalamic Acid · Watersol., Nephrotropic, High Osm. X-Ray Contr. Media | 41 | 1 |
| V08AD | Ethyl Esters Of Iodised Fatty Acids · Iopydol | 2 | 1 |
| V08AC | Adipiodone · Iopanoic Acid · Sodium Iopodate | 6 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ISOVUE 128 INJ 26% called?
The same molecule, Iopamidol, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| IOPAMIRON | Latin | Brazil |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.